[摘要] 目的 探讨二肽基肽酶-4抑制剂(DPP-4)对T2DM患者的临床疗效及安全性。 方法 对32例口服降糖药及胰岛素治疗血糖控制不佳的T2DM患者使用DPP-4治疗 12 周，测定治疗前后BMI、SBP、DBP、TC、TG、FPG、2 hPG、Scr、谷丙转氨酶(AST)、HbA1c、FC-P及2 hC-P。同时计算胰岛素抵抗指数(HOMA-IR)及胰岛β细胞功能指数[HOMA-β(C-P)]。 结果 12周后FPG[(7.94±0.52)mmol/L]、2 hPG[(12.29±1.07)mmol/L]、HbA1c[(8.44±0.50)%]，较治疗前均下降(P<0.01)，FC-P及2 hC-P水平[(6.52±0.13)、(7.83±0.17)pom/L)及HOMA-β(C-P)均增加(P<0.01)。研究期间均无严重低血糖事件发生。 结论 联合应用DPP-4可降低T2DM 患者FPG、2 hPG、HbA1c，同时能改善胰岛β细胞功能，且无明显不良反应，安全性较好。

　　[关键词]糖尿病, 2 型;二肽基肽酶-4抑制剂

　　【Abstract】Objective To evaluate the effect and safety of oral hypoglycemic agent,dipeptidyl peptidase-4 inhibitor(DPP-4), in the treatment of T2DM. Methods Thirty-two patients, with mild to moderate hyperglycemia, were given sitagliptin 100 mg once daily for 12 weeks. The indices including BMI, SBP，DBP, TC, TG, FPG, 2 hPG, Scr, AST, HbA1c,FC-P, and two-hour postprandial C-peptide (2 hC-P) before and after the treatment were measured for comparison. HOMA-IR and HOMA-βwere calculated too. Results The FPG[ (7.94±0.52) ] mmol/L, 2 hPG [ (12.29±1.07) ]mmol/L, and HbA1c[ (8.44±0.50)% ]decreased significantly after the treatment (P<0.01). FC-P and 2 hC-P[ (6.52±0.13),( 7.83±0.17) ]pom/L and (HOMA-β) increased significantly (P<0.01). There was no severe hypoglycemic episode. Conclusion DPP-4 used in combination decreases the level of FPG, 2 hPG, and HbA1c and improves the islet β cell functions. Its effect and safety are good.

　　【Key words】Diabetes mellitus, type 2; Dipeptidyl peptidase-4 inhibitor